HCV-G3: Sofosbuvir with ledipasvir or daclatasvir?

Size: px
Start display at page:

Download "HCV-G3: Sofosbuvir with ledipasvir or daclatasvir?"

Transcription

1 HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis

2 HCV genotype 3 therapy Chronic infection with HCV genotype 3 is common around the world Recent data showed that there is an increasing prevalence in Greece Associated with an increased risk of progression to steatosis, cirrhosis and HCC compared with other HCV genotypes (including gen 1) In the past it was considered that treatment of HCV genotype 3 patients is easier compared to HCV gen 1 & 4 Raptopoulou M et al, Hippokratia 211; Kanwal F et al, Hepatology 214

3 Treatment of HCV patients with genotype 3 IFN and RBV free therapy options are limited Results of treatment in genotype 3 patients with the first line of the all-oral therapy not optimal Effect of fibrosis stage difficulties in cirrhosis Efforts to improve SVR results Role of Peg-IFN+RBV+DAA Choice of DAA added to SOF What we expect in the coming future

4 SVR 12 in GT-3 naïve pts by fibrosis level and treatment scheme FISSION & VALENCE studies Overall No cirrhosis Cirrrhosis SOF+RBV 24 wks SOF+RBV 12 wks PEGIFN+RBV 24 wks Lawitz et al, NEJM 213, Zeuzem et al, NEJM 214

5 SVR12 (%) VALENCE: SOF + RBV in IFN-Naive and IFN-Experienced Pts With GT3 HCV Phase III study: SOF + RBV for 24 weeks No cirrhosis Cirrhosis / 92 12/ wks Naive 85/ 98 29/ wks Tx Failures Zeuzem S, et al. N Engl J Med. 214

6 Efforts to improve SVR rates Role of PEG-IFN in genotype 3 patients Combination with RBV in treatment naïve F-F3 patients Combination with RBV + SOF in Cirrhotic patients Treatment experienced (including SOF failures)

7 Virologic response (%) SVR (%) PEG-IFN + RBV therapy RVR is associated with a high SVR rate GT-1 GT-2 GT-3 GT Patients with RVR RVR (week 4) GT-1 GT-2 GT-3 GT-4 Fried et al, J Hepatol 211

8 SOF + PegIFN + RBV in HCV GT 2 or 3 Treatment-Experienced Patients Phase 2 LONESTAR-2 Open-label, Phase 2 study of the efficacy of SOF + PegIFN+ RBV for 12 weeks in treatment-experienced patients with GT 2 or 3 GT 2/3 TE N=47 SOF + PegIFN + RBV -12 mg SVR12 Study Week No response guided therapy Mean age (range), y 56 (39 72) Male, n (%) 32 (68) White, n (%) 45 (96) Hispanic, n (%) 21 (45) Mean BMI (range), kg/m 2 31 (21 53) IL28B CC, n (%) 17 (36) HCV GT 3, n (%) 24 (51) Mean BL HCV RNA (range), log 1 IU/mL 6 (4 7) Cirrhosis, n (%) 26 (55) Prior relapse/breakthrough, n (%) 4 (85) Lawitz E et al, Hepatology 214

9 SVR12 (%) SOF + PegIFN + RBV in HCV GT 3 Treatment-Experienced Pts LONESTAR-2 Virologic Response /24* 1/12 1/12 *2 relapses (1 with cirrhosis); 2 lost to follow-up1/12 GT 3 Overall Non-cirrhotic Cirrhotic Lawitz E et al, Hepatology 214

10 Patients with < LLOQ (%) SOF + PEG-IFN/RBV in previous SOF+RBV failures No Cirrhosis Cirrhosis /14 7/8 17/23 7/15 12 weeks SOF + PEG/RBV 24 weeks SOF+RBV Esteban et al, EASL 214

11 SVR12 (%) BOSON: Is SOF + PegIFN/RBV for 12 Wks Superior to SOF + RBV for 24 Wks in GT3? SOF + RBV for 24 wks SOF + pegifn/rbv for 12 wks Treatment Naive Treatment Experienced n/n = 65/ 72 68/ 71 18/ 22 21/ 23 No Cirrhosis Cirrhosis No Cirrhosis Cirrhosis 44/ 54 49/ 52 26/ 34 3/ 35 Foster GR, et al. Gastroenterology. 215;149:

12 Newer IFN-free combinations

13 EC5 s for NS5A inhibitors against HCV genotype 3 Drug 1a 1b 3a 4 Daclatasvir Ledipasvir GS MK ACH <.2 <.2 IDX ABT Gao et al, Curr Opin Virol 213 Ng et al, CROI 214

14 Study AI444-4 (phase ΙΙ): DCV + SOF ± RBV in naïve patients with GT 3 Main endpoint: SVR12 after 24w of treatment n=16 7d Follow-up LI B: 7 d Lead-in SOF, then DCV+SOF Follow-up Naïve GT2/3 HCV patients (n=44) n=14 n=14 D: DCV+SOF Follow-up F: DCV+SOF+RBV Follow-up Week 24 SVR12 RBV: -12 mg/d, weight-based (GT 1); 8 mg/d (GT 2/3). GT = genotype, DCV = daclatasvir, SOF = sofosbuvir (GS-7977), RBV = ribavirin,. Sulkowski MS et al (214) N Engl J Med;37:211-21

15 HCV RNA <LLOQ Ασθενείς, % Main endpoint: Naïve patients with SVR12 (mitt) GT2,3 B D F Lead-in SOF+DCV (24εβδ) DCV+SOF (24εβδ) DCV+SOF+RBV (24εβδ) N = 14/16 14/14 12/14 Naïve patients GT2, GT3 Comparable SVR12 rates in subgroups according to viral genotype : 92% (24/26) GT2 89% (16/18) GT3 LLOQ = κατώτερο όριο ποςοτικοποίηςησ (25 IU/mL), SOF = sofosbuvir, DCV = daclatasvir, RBV = ribavirin, EOT = τζλοσ τησ θεραπείασ, SVR = διαρκή ιολογική ανταπόκριςη. Sulkowski MS et al (214) N Engl J Med

16 SVR12 (%) ALLY-3: SOF + DCV x 12 Wks in Tx-Naive and Tx- Experienced Pts With GT3 HCV N = 152 pts with GT3 HCV 66% tx naive, 34% experienced 19% of tx-naive pts and 25% of tx-experienced pts had cirrhosis 61% of tx-experienced pts relapsed on previous therapy, 14% had null response 1 SAE, grade 3/4 lab abnormalities in 2% of pts Nelson DR, et al. AASLD 214. Abstract LB-3.

17 ALLY-3: Results No cirrhosis Cirrhosis Overall Tx Naive Tx Experienced Nelson DR, et al. AASLD 214. Abstract LB-3.

18 ALLY-3+ ALLY-3+ Study Design Phase 3b, open-label, randomized study 1:1 randomization (N = 5) Stratified by fibrosis stage (F3 or F4) DCV + SOF + RBV 12 weeks DCV + SOF + RBV 16 weeks 24-week follow-up 24-week follow-up DCV 6 mg daily N = 5 SOF 4 mg daily RBV (weight-based 12 or mg/day) Primary efficacy endpoint: SVR12 HCV RNA <LLOQ TD/TND (next observation carried backward) by Roche COBAS TaqMan v2. assay (LLOQ 25 IU/mL) Patient population Naïve 26% Week Experienced 76% (SOF-based regimens 12%) Leroy V, et al. AASLD 215. Abstract LB-3.

19 HCV RNA < LLOQ TD/TND (%) ALLY-3+ SVR12: All Treated Patients ITT ANALYSIS (Primary Endpoint) Overall 12 Weeks 16 Weeks VBT a Relapse b Death c 1 1 Leroy V, et al. AASLD 215. Abstract LB-3.

20 HCV RNA < LLOQ TD/TND (%) HCV RNA < LLOQ TD/TND (%) ALLY-3+ SVR12: All Treated Patients ITT ANALYSIS (Primary Endpoint) OBSERVED ANALYSIS Overall 12 Weeks 16 Weeks Overall 12 Weeks 16 Weeks VBT a Relapse b VBT a Relapse b Death c 1 1 Leroy V, et al. AASLD 215. Abstract LB-3.

21 HCV RNA < LLOQ TD/TND (%) SVR12: Patients with Advanced Fibrosis a ALLY Overall 12 Weeks 16 Weeks 8 8 Leroy V, et al. AASLD 215. Abstract LB-3.

22 HCV RNA < LLOQ TD/TND (%) ALLY-3+ SVR12: Patients with Cirrhosis ITT ANALYSIS Overall 12 Weeks 16 Weeks VBT a Relapse b Death c 1 1 Leroy V, et al. AASLD 215. Abstract LB-3.

23 HCV RNA < LLOQ TD/TND (%) HCV RNA < LLOQ TD/TND (%) ALLY-3+ SVR12: Patients with Cirrhosis ITT ANALYSIS Overall 12 Weeks 16 Weeks VBT a Relapse b Death c OBSERVED ANALYSIS VBT Relapse Overall 12 Weeks 16 Weeks Leroy V, et al. AASLD 215. Abstract LB-3.

24 LDV/SOF + RBV combination in treatment naïve & experienced genotype 3 patients W W12 W24 Treatment-naïve n=25 Treatment-naïve n=26 Treatment experienced n=5 LDV/SOF LDV/SOF + RBV LDV/SOF + RBV SVR12 SVR12 SVR12 Inclusion of patients with cirrhosis Broad inclusion criteria: No upper limit for age or BMI PLT>5./mm 3 Gane EJ et al, Gastroenterology 215

25 Results SVR /25 26/26 41*/5 Rx naïve LDV + SOF Rx naive LDV+SOF +RBV Rx experienced LDV+SOF +RBV *One patient with virologic breakthrough on treatment week 12 All the rest patients with virologic relapse Gane EJ et al, Gastroenterology 215

26 LDV/SOF + RBV combination in treatment experienced genotype 3 patients SVR Total Without cirrhosis Cirrhosis One patient with virologic breakthrough on treatment week 12 All the rest patients with virologic relapse Gane EJ et al, Gastroenterology 215

27 SOF +DCV /LDV + RBV in patients with advanced liver disease Real-life experience

28 SOF+NS5A±RBV for 12 Weeks in 467 Patients with History of Decompensated Cirrhosis GT 1 N=235 GT 3 N=189 Other GTs N=43 Foster, EASL, 215, O2 Total N=467 Mean age, years (range) 56.1 (29-76) 54 (36-75) 59 (36-81) 55.6 (29-81) Male gender, n (%) 174 (74.) 131 (69.3) 32 (74.4) 337 (72.2) Treatment experienced, n (%) 17 (45.5) 88 (46.6) 25 (58.1) 22 (47.1) Liver transplanted, n (%) 27 (11.5) 15 (7.9) 5 (11.6) 47 (1.1) Past or present decompensated cirrhosis, n (%) 223 (94.9) 179 (94.7) 39 (9.7) 441 (94.4) CTP B, n (%) 161 (68.5) 121 (64.) 27 (62.8) 39 (66.2) CTP C, n (%) 19 (8.1) 24 (12.7) 3 (7.) 46 (9.9) MELD mean (range) 11.9 (6-36) 11.3 (6-24) 12.6 (6-36) 11.9 (6-36) Active ascites, n (%) 97 (41.3) 67 (35.4) 14 (32.6) 178 (38.1) Previous variceal bleed, n (%) 61 (26.) 55 (29.1) 11 (25.6) 127 (27.2) Active encephalopathy, n (%) 41 (17.4) 34 (18.) 5 (11.6) 8 (17.1) Treatment, n (%)* LDV/SOF+RBV SOF+DCV+RBV SOF+NS5A without RBV *Choice of therapy was at clinician's discretion 164 (35.1) 45 (9.6) 26 (5.6) 61 (13.1) 114 (24.4) 14 (3.) 27 (5.8) 13 (2.8) 3 (.6) 252 (54) 172 (36.8) 43 (9.2)

29 SVR12, % SVR12 in GT 1 Patients with History of Decompensated Cirrhosis /21 141/164 3/5 37/45 LDV/SOF LDV/SOF +RBV Majority of patients received RBV SOF+DCV SOF+DCV +RBV LDV/SOF±RBV for 12 weeks resulted in high SVR rates in GT 1 decompensated cirrhotics Foster, EASL, 215, O2

30 SVR12, % SVR12 in GT 3 Patients with History of Decompensated Cirrhosis /7 36/61 5/7 8/114 LDV/SOF LDV/SOF +RBV Majority of patients received RBV SOF+DCV SOF+DCV +RBV SVR rates were comparable to those seen in other studies of SOF+NS5A±RBV for 12 weeks in decompensated cirrhotics Foster, EASL, 215, O2

31 Changes in MELD Score MELD Improvement in GT 1 and 3 Patients with History of Decompensated Cirrhosis 15 1 Non-transplanted Transplanted on treatment 5 n = 131 n = 33-5 n = Number of Patients -2 Improvement of > 2 MELD scores was observed in 41% by FU Week 4 and 48% had no significant changes Foster, EASL, 215, O2

32 European DCV Compassionate Use Program Primary objective: To provide access to DCV to patients with life-threatening chronic HCV infection who have no other treatment options Day 1 Week 24 # Week 36 Week 48 Week 72 DCV (6 mg)* + SOF (4 mg) ± RBV # Follow-Up Additional Optional Follow-Up SVR12 Primary endpoint SVR24 * Dose adjusted for concomitant ARVs # Addition of RBV and shorter duration of HCV RNA < LLOQ, TD or TND at post treatment Week 12 treatment at the discretion of the physician (next value carried backward approach) Inclusion criteria Age 18 years with no treatment options High risk of hepatic decompensation or death within 12 months if left untreated Or urgent need of viral clearance (extrahepatic manifestations/comorbidities) Exclusion criteria Creatinine clearance 3 ml/min Pregnancy or not using contraception Welzel et al, AASLD 215

33 HCV RNA < LLOQ, TD or TND, % SVR12 (mitt) in Patients With Cirrhosis DCV + SOF DCV + SOF + RBV Cirrhosisᵃ A B C < 1 1 to 15 > 15 Child-Pugh Class MELD Score Category b 2 2 Welzel et al, AASLD 215

34 g/l platelets 1 9 /L IU/L mol/l Changes in Liver Disease Parameters From Baseline to Post-Treatment Week ALT ALT Baseline Follow-up n = n = Total Bilirubin Total Bilirubin Baseline Follow-up n = 75 n = Albumin Albumin Baseline Follow-up n = 87 n = 6 Data indicate median, IQR, range Platelets Platelets Baseline Follow-up n = 11 n = 7 Welzel et al, AASLD 215

35 What we expect in the near future

36 SOF/VEL STR for 12 Weeks Compared to SOF+RBV for 24 Weeks in GT 3 HCV-Infected Patients Phase 3, open-label, randomized study of SOF/VEL for 12 weeks in GT 3 Week n=277 SOF/VEL SVR12 n=275 SOF + RBV SVR12 SOF/VEL 12 Weeks n=277 SOF + RBV 24 Weeks n=275 Mean age, y (range) 49 (21 76) 5 (19 74) Male, n (%) 17 (61) 174 (63) White, n (%) 25 (9) 239 (87) Mean BMI, kg/m 2 (range) 26.4 ( ) 26.6 ( ) Cirrhosis, n (%) 8 (29) 83 (3) Treatment experienced, n (%) 71 (26) 71 (26) IL28B CC, n (%) 15 (38) 111 (4) HCV RNA, log 1 IU/mL (SD) 6.2 (.7) 6.3 (.7) 36 Mangia, AASLD, 215, 249. Foster GR, et al. New Engl J Med. 215

37 SVR12 (%) SVR12 P< relapse 2 other 38 relapse 1 BT 15 other 2 BT=breakthrough 264/ /275 SOF/VEL SOF + RBV 12 Weeks 24 Weeks Mangia, AASLD, 215, 249. Foster GR, et al. New Engl J Med. 215

38 SVR12 (%) SVR12 by Cirrhosis Status and 8 Treatment History SOF/VEL SOF + RBV / /156 4/43 33/45 31/34 22/31 33/37 22/38 264/ /275 Non-Cirrhotic Cirrhotic Non-Cirrhotic Cirrhotic Overall Treatment Naïve Treatment Experienced Mangia, AASLD, 215, 249. Foster GR, et al. New Engl J Med. 215

39 Adapted from the Wyles presentation at AASLD on November 17, 215 SURVEYOR-II Part 1 (GT3): Study Design SURVEYOR-II Part 1 (GT3): Study Design SURVEYOR-II is an open-label, multicenter phase 2 trial evaluating the safety and efficacy of co-administered ABT-493 and ABT-53, at varying doses, ± ribavirin (RBV), in HCV treatment-naïve or failed previous PegIFN/RBV treatment, noncirrhotic patients with HCV GT2 or GT3 infection Absence of cirrhosis Day 1 Week 12 PT Week 24 Treatment period Post-treatment (PT) period n=3 n=3 a n=31 n=3 ABT mg + ABT mg ABT mg + ABT mg ABT mg + ABT mg + RBV b ABT mg + ABT-53 4 mg ClinicalTrials.gov: NCT N=121. a Includes one patient who was incorrectly assigned to treatment in the GT2 cohort. b Daily dose of mg or 12 mg RBV dosed BID based on patient body weight being <75 kg or 75 kg.

40 S V R 1 2, % P a t ie n t s 1 SURVEYOR-II Part 1 (GT3): ITT SVR12 Rates by Treatment (ITT) ABT ABT mg + 12 mg mg + 12 mg mg + 12 mg + RBV mg + 4 mg Adapted from the Wyles presentation at AASLD on November 17, 215

41 SURVEYOR-II Part 1 (GT3): ITT SVR12 Rates by Treatment (per Protocol*) Wyles et al, AASLD 215

42 SVR12 (%) N = 24 Treatmentnaive GT-1, -2 and -3 Non-cirrhotic C-CREST-1 and 2 Part A: GRZ and MK-3682 in patients with chronic HCV GT-1, -2 or -3 GT-3 (n) GZR + EBR + MK mg GZR + EBR + MK mg GZR + MK-848 +MK mg GZR + MK-848 +MK mg Follow-up Follow-up Follow-up Follow-up Safety (Overall population) The most frequent study drug-related AEs in > 1% of all patients were headache (23%), fatigue (2%) and nausea (13%) There were no drug-related serious adverse events, no patients discontinued due to adverse events and no patients died Week SVR12 in GT-3 patients GZR + EBR + MK mg GZR + EBR + MK mg GZR + MK MK mg GZR + MK MK mg Gane E, et al. AASLD 215, Abstract LB-15.

43 SOF/VEL + GS and 8 weeks treatment for cirrhotic gen 3 patients W W6 W8 W18 W2 TN - cirrhosis n=18 SOF/VEL+GS-9857 SVR12 TE cirrhosis n=18 SOF/VEL+GS-9857 SVR12 Gane et al, AASLD 215

44 Results: SVR 12 rates 15/ */18 SVR 12 19/19 TN- cirrhosis 6 weeks TE-cirrhosis 8 weeks *2 relapses; 1 withdrew consent Gane et al, AASLD 215

45 Conclusions (1) PEG-IFN + RBV has still a role for patients with genotype 3 Dual combination ONLY in naïve GT 3 pts with mild fibrosis and RVR PEG-IFN+RBV+SOF for 12 wks in GT-3 is an optimal choice for: Treatment naïve and experienced pts even with cirrhosis Previous failure to SOF + RBV Less expensive than all oral 2DAAs combination for 12/24 weeks

46 Conclusions (2) Optimal IFN free treatment schemes for treatment-naïve and experienced patients without cirrhosis: SOF/LDV + RBV for 12 weeks SOF + DCV for 12 weeks Presence of cirrhosis still an unresolved issue PEG-IFN + RBV + SOF for 12 weeks SOF + DCV + RBV for weeks Hope from novel agents Most awaited data from SOF + VEL + GS-9857 combination

47

Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos

Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology

More information

TREATMENT OF GENOTYPE 2

TREATMENT OF GENOTYPE 2 Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,

More information

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding

More information

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on

More information

Latest Treatment Updates for GT 2 and GT 3 Patients

Latest Treatment Updates for GT 2 and GT 3 Patients Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of

More information

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients 5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,

More information

Hepatitis C in Special Populations

Hepatitis C in Special Populations Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health

More information

Treatments of Genotype 2, 3,and 4: Now and in the future

Treatments of Genotype 2, 3,and 4: Now and in the future Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve

More information

Rome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING

Rome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN

More information

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle

More information

HCV In 2015: Maximizing SVR

HCV In 2015: Maximizing SVR HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last

More information

Treating now vs. post transplant

Treating now vs. post transplant Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence

More information

Treatment of Unique Populations Raymond T. Chung, MD

Treatment of Unique Populations Raymond T. Chung, MD Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research

More information

HCV Management in Decompensated Cirrhosis: Current Therapies

HCV Management in Decompensated Cirrhosis: Current Therapies Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu

More information

Why make this statement?

Why make this statement? HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed

More information

Associate Professor of Medicine University of Chicago

Associate Professor of Medicine University of Chicago Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death

More information

Approved regimens for cirrhotic patients

Approved regimens for cirrhotic patients 5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis

More information

Hepatitis C Treatment 2014

Hepatitis C Treatment 2014 Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype

More information

Treatment of HCV in 2016

Treatment of HCV in 2016 5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,

More information

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor

More information

Addressing Unmet Medical Needs in HCV Genotype 3

Addressing Unmet Medical Needs in HCV Genotype 3 Addressing Unmet Medical Needs in HCV Genotype 3 Karen Doucette, MD, MSc (Epi), FRCPC Associate Professor, Division of Infectious Diseases, Department of Medicine University of Alberta Objectives Identify

More information

Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty

Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn

More information

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate

More information

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade

More information

Treating HCV After Liver Transplantation: What are the Treatment Options?

Treating HCV After Liver Transplantation: What are the Treatment Options? 4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital

More information

Antiviral treatment in HCV cirrhotic patients on waiting list

Antiviral treatment in HCV cirrhotic patients on waiting list Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory

More information

Duncan Webster, BSc, BA, MA, MD, FRCPC

Duncan Webster, BSc, BA, MA, MD, FRCPC Moderator Duncan Webster, BSc, BA, MA, MD, FRCPC Internist, Infectious Disease Physician, Department of Medicine Medical Microbiologist, Department of Laboratory Medicine, Saint John Regional Hospital

More information

Management of HCV Tawesak Tanwandee

Management of HCV Tawesak Tanwandee Management of HCV 2016 Tawesak Tanwandee Topics Burden of HCV in our countries Natural history and unmet need for HCV treatment Current treatment as for 2016 Conclusion Evolution from HCV infection to

More information

Saeed Hamid, MD Alex Thompson, MD, PhD

Saeed Hamid, MD Alex Thompson, MD, PhD Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-

More information

Future strategies with new DAAs

Future strategies with new DAAs Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks

More information

Expert Perspectives: Best of HCV from EASL 2015

Expert Perspectives: Best of HCV from EASL 2015 Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and

More information

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients

More information

VIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015

VIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research

More information

Dr. Siddharth Srivastava

Dr. Siddharth Srivastava Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.

More information

The HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)

The HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1) Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell

More information

HCV Update from AASLD 2016

HCV Update from AASLD 2016 HCV Update from AASLD 2016 Ahmed Elsharkawy Consultant Hepatologist QE Birmingham Secretary and Chair-Elect of BVHG BHIVA/BVHG Feedback Meeting November 2016 Speaker Name Ahmed Elsharkawy Statement Speaking

More information

Pivotal New England Journal of Medicine papers 2014 Phase 3 Trial data

Pivotal New England Journal of Medicine papers 2014 Phase 3 Trial data 4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:

More information

DAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo

DAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo DAAs in the era of decompensated liver disease Piero L. Almasio University of Palermo piero.almasio@unipa.it HCV therapy in the era of interferon based therapy Priority Compensated cirrhosis Decompensated

More information

Ledipasvir-Sofosbuvir (Harvoni)

Ledipasvir-Sofosbuvir (Harvoni) HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical

More information

What Should We Do With Difficult to Treat HCV Populations?

What Should We Do With Difficult to Treat HCV Populations? What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah

More information

Hepatitis C Emerging Treatment Paradigms

Hepatitis C Emerging Treatment Paradigms Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,

More information

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370: Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV

More information

HCV Treatment in 2016

HCV Treatment in 2016 HCV Treatment in 2016 Hugo E. Vargas, MD Professor of Medicine Mayo College of Medicine Medical Director, Clinical Trials Office Vice Chair, Department of Research Educational Goals Caveats: Cannot cover

More information

10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection

10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:

More information

SOLAR-1 (Cohorts A and B)

SOLAR-1 (Cohorts A and B) Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; 149:649-59. Ledipasvir-Sofosbuvir

More information

Evolution of Therapy in HCV

Evolution of Therapy in HCV Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR

More information

Treating HCV Genotype 2 & 3

Treating HCV Genotype 2 & 3 Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy

More information

STATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD

STATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators

More information

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir

More information

10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives

10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16

More information

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir

More information

8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV

8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology

More information

SOLAR-1 (Cohorts A and B)

SOLAR-1 (Cohorts A and B) Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; [Epub ahead of print]

More information

CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015

CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases, November

More information

Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona

Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives

More information

Current Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany

Current Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,

More information

NS5A inhibitors: ideal candidates for combination?

NS5A inhibitors: ideal candidates for combination? NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang

More information

Failure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016

Failure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016 Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,

More information

Case 2: A 71-year-old man with cirrhosis

Case 2: A 71-year-old man with cirrhosis Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years

More information

Rapid Response from San Francisco: The Latest in the HCV Treatment Revolution

Rapid Response from San Francisco: The Latest in the HCV Treatment Revolution Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful

More information

A treatment revolution: current management for chronic HCV

A treatment revolution: current management for chronic HCV A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research

More information

HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London

HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown

More information

Learning Objective. After completing this educational activity, participants should be able to:

Learning Objective. After completing this educational activity, participants should be able to: Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential

More information

HCV Treatment of Genotype 1: Now and in the Future

HCV Treatment of Genotype 1: Now and in the Future HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program

More information

IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?

IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University

More information

O. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki

O. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki O. Giouleme Assistant Professor of Gastroenterology Ippokration General Hospital of Thessaloniki Disclosures Advisory Board: Abbvie Pharmaceuticals Speaker: Gilead Sciences, Bristol-Myers Squibb Research

More information

Clinical Management: Treatment of HCV Mono-infection

Clinical Management: Treatment of HCV Mono-infection Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry

More information

Interferon-based and interferon-free new treatment options

Interferon-based and interferon-free new treatment options Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt

More information

4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives

4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives 4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215

More information

Update on chronic hepatitis C treatment: current trends, new challenges, what next?

Update on chronic hepatitis C treatment: current trends, new challenges, what next? Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15

More information

HCV: Current SOTA of Management of Treatment Experienced Patients

HCV: Current SOTA of Management of Treatment Experienced Patients HCV: Current SOTA of Management of Treatment Experienced Patients Robert G Gish MD Professor Consultant Stanford University Executive Committee: National Viral Hepatitis Roundtable Founding Member: CEVHAP

More information

Tough Cases in HIV/HCV Coinfection

Tough Cases in HIV/HCV Coinfection NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014

More information

HCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD

HCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,

More information

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients 2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director

More information

Transformation of Chronic Hepatitis C Treatment

Transformation of Chronic Hepatitis C Treatment Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence

More information

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Goals for Hepatitis C Therapy Compared to PegIFN/RBV, new products should offer: Improved efficacy Efficacy in all patient types including

More information

Feeling right at home

Feeling right at home Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements

More information

Hepatitis C: New Therapies in

Hepatitis C: New Therapies in Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and

More information

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation

More information

EASL and The Future of HCV Treatment

EASL and The Future of HCV Treatment EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine

More information

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,

More information

SYNOPSIS Final Clinical Study Report for Study AI444031

SYNOPSIS Final Clinical Study Report for Study AI444031 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study

More information

HCV therapy : Clinical case

HCV therapy : Clinical case HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah

More information

HCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland

HCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier

More information

Introduction. The ELECTRON Trial

Introduction. The ELECTRON Trial 63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver

More information

Clinical Studies and Recent Real-World Data with Sofosbuvir/Ledipasvir

Clinical Studies and Recent Real-World Data with Sofosbuvir/Ledipasvir Clinical Studies and Recent Real-World Data with Sofosbuvir/Ledipasvir Kalliopi Zachou Assistant Professor of Medicine University of Thessaly Disclosures Speaker s bureau and advisory: Gilead Bristol History

More information

47 th Annual Meeting AISF

47 th Annual Meeting AISF 47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,

More information

Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London

Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London IFN free therapy Disclosures I have received personal and institutional funding from companies that sell drug

More information

6/2/2015. Interactive Case-Based Presentations and Audience Discussion

6/2/2015. Interactive Case-Based Presentations and Audience Discussion Interactive Case-Based Presentations and Audience Discussion Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,

More information

Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD

Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors

More information

Update in the Management of Hepatitis C: What Does the Future Hold

Update in the Management of Hepatitis C: What Does the Future Hold Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana

More information

Can we afford to Cure all HIV-HCV Co-infected Patients of HCV?

Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr

More information

PIB. Next Generation Direct-Acting Antivirals. Collectively: G/P. Pibrentasvir (formerly ABT-530) pangenotypic NS5A inhibitor

PIB. Next Generation Direct-Acting Antivirals. Collectively: G/P. Pibrentasvir (formerly ABT-530) pangenotypic NS5A inhibitor Surveyor-II, Part 3: Efficacy and Safety of Glecaprevir/Pibrentasvir (Abt-493/Abt-53) in Patients with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience and/or Cirrhosis David L. Wyles,

More information

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center

More information

ICVH 2016 Oral Presentation: 28

ICVH 2016 Oral Presentation: 28 Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K

More information

A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran

A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs

More information

Treatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

Treatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Treatment of Hepatitis C Recurrence after Liver Transplantation Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Agenda 1. Introduction 2. Treatment options for hepatitis C recurrence after transplantation

More information

HEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation

HEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences

More information

The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago

The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should

More information

HCV treatment options in clinical practice. Current treatment options for HCV-G4

HCV treatment options in clinical practice. Current treatment options for HCV-G4 HCV treatment options in clinical practice Current treatment options for HCV-G4 C. Triantos Gastroenterology Department University Hospital of Patras Conflicts of interest Speaker and research/travel grants

More information